Every 10-Q that agilon health, inc. (AGL) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AGL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AGL filings page.
agilon health (AGL) reported Q3 2025 results showing continued top-line scale with pressure on medical costs. Total revenue was $1.4 billion, while medical services expense of $1.49 billion drove a gross loss of $67.6 million. Net loss was $110.2 million (basic and diluted EPS $(0.27)).
Medicare Advantage membership was 502,800, down 4% year over year. Adjusted EBITDA loss was $91 million. Cash and cash equivalents were $171.7 million with marketable securities of $139.2 million as of September 30, 2025. Medical claims and related payables rose to $1,059.4 million, reflecting ongoing utilization and IBNR estimates. Shares outstanding were 414,570,000 at quarter end and 414,581,604 at October 30, 2025.
On liquidity, the company had $35.0 million outstanding under its term loan and $83.2 million of standby letters of credit, leaving $16.8 million available on the revolving facility, which matures on February 18, 2026. The effective interest rate on the term loan was 8.272%.